Seeking Alpha

Lazard Capital sees huge potential in GW Pharmaceuticals' epilepsy program

  • Lazard Capital is excited about Sativex maker GW Pharmaceuticals (GWPH).
  • Market chatter suggests Joshua Schimmer has raised his price target on the shares to $65 (from $22) for upside potential of 163%.
  • Apparently, the company's Otsuka-partnered (OTSKF.OB) epilepsy program is "one of the most compelling opportunities [Lazard] has ever seen."
  • Here's what the company has to say about that program: "By studying the impact of cannabinoid addition on the amplitude of the epileptiforms produced, researchers are able to recognize if compounds could perform as an anti-epileptic drug in vivo."
Comments (3)
  • Goggin
    , contributor
    Comments (48) | Send Message
     
    GWP's pipeline includes treatment for cancer pain, Phase I!! trials underway for possible FDA application in 2014, and many other medications in various lab and clinical trials. Some physiological, some psychological.
    7 Oct 2013, 09:44 AM Reply Like
  • Way Zoo
    , contributor
    Comments (14) | Send Message
     
    GW is a game changer in the pharma industry.
    7 Oct 2013, 11:15 AM Reply Like
  • Sparkt_99
    , contributor
    Comments (693) | Send Message
     
    I love GW!!! thanks Lazard!
    7 Oct 2013, 02:04 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector